Pathogenesis of epidermolysis bullosa acquisita

Dermatologic Clinics

Volumn 29, Issue 3, 2011, Pages 493-501

  Ludwig, Ralf J ^a   Zillikens, Detlef ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Animal model; Autoimmunity; Blister; Epidermolysis bullosa acquisita; Skin

Indexed keywords

AUTOANTIBODY; COLLAGEN TYPE 7;

AUTOIMMUNE SKIN DISEASE; BULLOUS SKIN DISEASE; COMPLEMENT ACTIVATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LEUKOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; SKIN;

EID: 79956283478     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2011.03.003     Document Type: Review

References (46)

1. Elliott G.T. Two cases of epidermolysis bullosa. J Cutan Genitourin Dis 1895, 13:10.
2. Roenigk H.H.J., Ryan J.G., Bergfeld W.F. Epidermolysis bullosa acquisita. Report of three cases and review of all published cases. Arch Dermatol 1971, 103:1-10.
3. Woodley D.T., Briggaman R.A., O'Keefe E.J., et al. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984, 310:1007-1013.
4. Woodley D.T., Burgeson R.E., Lunstrum G., et al. Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest 1988, 81:683-687.
5. Lapiere J.C., Woodley D.T., Parente M.G., et al. Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 1993, 92:1831-1839.
6. Gammon W.R., Murrell D.F., Jenison M.W., et al. Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J Invest Dermatol 1993, 100:618-622.
7. Chen M., Doostan A., Bandyopadhyay P., et al. The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita. Am J Pathol 2007, 170:2009-2018.
8. Ishii N., Yoshida M., Hisamatsu Y., et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol 2004, 150:843-851.
9. Ishii N., Yoshida M., Ishida-Yamamoto A., et al. Some epidermolysis bullosa acquisita sera react with epitopes within the triple-helical collagenous domain as indicated by immunoelectron microscopy. Br J Dermatol 2009, 160:1090-1093.
10. Jones D.A., Hunt S.W., Prisayanh P.S., et al. Immunodominant autoepitopes of type VII collagen are short, paired peptide sequences within the fibronectin type III homology region of the noncollagenous (NC1) domain. J Invest Dermatol 1995, 104:231-235.
11. Sitaru C., Kromminga A., Hashimoto T., et al. Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol 2002, 161:301-311.
12. Sitaru C., Mihai S., Otto C., et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005, 115:870-878.
13. Woodley D.T., Chang C., Saadat P., et al. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005, 124:958-964.
14. Woodley D.T., Ram R., Doostan A., et al. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol 2006, 126:1323-1330.
15. Sitaru C., Chiriac M.T., Mihai S., et al. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 2006, 177:3461-3468.
16. Kasperkiewicz M., Hirose M., Recke A., et al. Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita. Br J Dermatol 2010, 162:1064-1070.
17. Ludwig R.J., Recke A., Bieber K., et al. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J Invest Dermatol 2011, 131(1):167-176.
18. Fernando M.M., Stevens C.R., Walsh E.C., et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008, 4:e1000024.
19. Gammon W.R., Heise E.R., Burke W.A., et al. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol 1988, 91:228-232.
20. Connolly K., Roubinian J.R., Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol 1992, 149:3083-3088.
21. Takahashi H., Amagai M., Nishikawa T., et al. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris. J Immunol 2008, 181:1526-1535.
22. Groom J., Mackay F. B cells flying solo. Immunol Cell Biol 2008, 86:40-46.
23. Herlands R.A., Christensen S.R., Sweet R.A., et al. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008, 29:249-260.
24. Muller R., Dahler C., Mobs C., et al. T and B cells target identical regions of the non-collagenous domain 1 of type VII collagen in epidermolysis bullosa acquisita. Clin Immunol 2010, 135:99-107.
25. Sitaru A.G., Sesarman A., Mihai S., et al. T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. J Immunol 2010, 184:1596-1603.
26. Abrams M.L., Smidt A., Benjamin L., et al. Congenital epidermolysis bullosa acquisita: vertical transfer of maternal autoantibody from mother to infant. Arch Dermatol 2010.
27. Ambrosius H., Hadge D. Chicken immunoglobulins. Vet Immunol Immunopathol 1987, 17:57-67.
28. Sesarman A., Mihai S., Chiriac M.T., et al. Binding of avian IgY to type VII collagen does not activate complement and leuckocytes fail to induce subepidermal blistering in mice. Br J Dermatol 2008, 158:463-471.
29. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005, 5753:1510-1512.
30. Bruhns P., Iannascoli B., England P., et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2008, 16:3716-3725.
31. Bernard P., Prost C., Aucouturier P., et al. The subclass distribution of IgG autoantibodies in cicatricial pemphigoid and epidermolysis bullosa acquisita. J Invest Dermatol 1991, 97:259-263.
32. Oostingh G.J., Sitaru C., Zillikens D., et al. Subclass distribution of type VII collagen-specific autoantibodies in patients with inflammatory bowel disease. J Dermatol Sci 2005, 37:182-184.
33. Cho H.J., Lee I.J., Kim S.C. Complement-fixing abilities and IgG subclasses of auto-antibodies in epidermolysis bullosa acquisita. Yonsei Med J 1998, 39:339-344.
34. Gandhi K., Chen M., Aasi S., et al. Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype. J Clin Immunol 2000, 20:416-423.
35. Recke A., Sitaru C., Vidarsson G., et al. Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation. J Autoimmun 2010, 34:435-444.
36. Mihai S., Chiriac M.T., Takahashi K., et al. The alternative pathway in complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol 2007, 178:6514-6521.
37. Schön M., Ludwig R.J. Lymphocyte trafficking to inflames skin-molecular mechanisms and implications for therapeutic target molecules. Expert Opin Ther Targets 2005, 9:225-243.
38. Chiriac M.T., Roesler J., Sindrilaru A., et al. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol 2007, 212:56-65.
39. Daley J.M., Thomay A.A., Connolly M.D., et al. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 2008, 83:64-70.
40. Radeke H.H., Ludwig R.J., Boehncke W.H. Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo. Exp Dermatol 2005, 14:641-666.
41. van Eeden S.F., Klut M.E., Walker B.A., et al. The use of flow cytometry to measure neutrophil function. J Immunol Methods 1999, 232:23-43.
42. Yu X., Holdorf K., Kasper B., et al. FcγRIIA and FcγRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid. J Invest Dermatol 2010, 130(12):2841-2844.
43. Shimanovich I., Mihai S., Oostingh G.J., et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004, 204:519-527.
44. Feliciani C., Toto P., Amerio P., et al. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Derm 2000, 114:71-77.
45. Ludwig R.J., Schmidt E. Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?. G Ital Dermatol Venereol 2009, 144:339-349.
46. Bieber K., Sun S., Ishii N., et al. Animal models for autoimmune bullous dermatoses. Exp Dermatol 2010, 19:2-11.